Andrew Hamer
Vermogen: 817 335 $ op 31-05-2026
Vermogen: 817 335 $ op 31-05-2026
Andrew Hamer is Chief Medical Officer, Head-Research & Development at Cardiol Therapeutics, Inc. since 2021.
Formerly, Dr. Hamer was Executive Director-Global Development at Amgen, Inc. from 2018 to 2021.
Dr. Hamer was Vice President-Medical Affairs at Capricor Therapeutics, Inc. from 2013 to 2015 and also held the position of Vice President-Medical Affairs at Capricor, Inc. Dr. Hamer completed undergraduate education at the University of Otago.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 03-12-2025 | 669.947 ( 0,6% ) | 817 335 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 29-03-2021 |
| Bedrijven | Functie | Einde |
|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 01-03-2021 |
| CAPRICOR THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 30-07-2015 |
Capricor, Inc.
Capricor, Inc. BiotechnologyHealth Technology Provides cardiac stem cell therapeutics biotechnology services | Hoofd Techniek/Wetenschap/O&O | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Capricor, Inc.
Capricor, Inc. BiotechnologyHealth Technology Provides cardiac stem cell therapeutics biotechnology services | Health Technology |
University of Otago
University of Otago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative products for the treatment of cardiovascular diseases | Health Technology |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau